UTv Videos

Charles R. Powell, MD, discusses how the rise of GLP-1–associated weight loss may influence outcomes and device management in sacral neuromodulation.

Akanksha Mehta, MD, MS, discusses why the updated vasectomy guideline expands its focus on fertility restoration, emphasizing patient counseling on reversal and individualized decision-making for future family building.

Adanma Ayanambakkam, MD, MS, discusses the FIT-001 trial and early findings on the safety profile for darlifarnib plus cabozantinib in ccRCC.

Helen L. Bernie, DO, MPH, discusses how expanded TRT labeling could improve care for men with idiopathic hypogonadism.

Nannan Thirumavalavan, MD, reflects on how the FDA’s testosterone labeling changes, informed by the TRAVERSE trial, have influenced TRT prescribing and clinician confidence over the past year.

Daniel J. George, MD, highlights survey findings on the role of caregivers in the treatment journey for patients with metastatic prostate cancer.

In this video, Dalia Kaakour, MD, MPH, highlights retrospective findings on the use of ctDNA in detecting residual disease and recurrence in testicular cancer.

In this video, Meri-Margaret Deoudes discusses ongoing challenges for patients with bladder cancer, including costs of care, delayed diagnoses among women, and access barriers among patients in rural areas.

Suction-enabled URS platforms and AI-driven prediction and planning tools represent 2 parallel frontiers in kidney stone management, with active fragment evacuation already in clinical use and artificial intelligence poised to reshape preoperative planning, patient selection, and intraoperative guidance.

Robert Flavell, MD, PhD, and Anil P. Bidkar, PhD, discuss the synergistic potential of CD46-directed alpha radiation and ADC therapy combination.

Akanksha Mehta, MD, MS, discusses AUA guideline recommendations for performing post-vasectomy semen analysis.

Neha Vapiwala, MD, FASTRO, discusses the integration of radiation therapy with systemic treatment intensification across different stages of localized and locally advanced prostate cancer.

Experts discuss the implications of the FDA’s potential pathway to expand testosterone replacement therapy labeling for low libido in men with idiopathic hypogonadism.

Kyle M. Rose, MD, discusses key considerations for optimizing the timing and sequencing of inguinal and pelvic lymph node dissection.

Akanksha Mehta, MD, MS, discusses updated recommendations from the 2026 AUA Vasectomy Guideline on vas isolation and occlusion techniques.

Fred Saad, MD, FRCS, discusses findings from a post hoc analysis of the phase 3 ARANOTE trial.

Medtronic's Touch Surgery enterprise platform, integrated with the Hugo robotic system, offers AI-driven case segmentation, real-time anatomic overlay, and two-way telementoring capabilities that James R. Porter, MD, describes as the most robust digital offering currently available on a robotic surgery platform.

Meri-Margaret Deoudes discusses findings from BCAN's New Faces of Bladder Cancer Report.

Daniel J. George, MD, highlights patient-reported outcomes and tolerability findings from the phase 3 CAPItello-281 trial, evaluating the addition of capivasertib to abiraterone in patients with PTEN-deficient de novo mHSPC.

Minas P. Economides, MD, discusses the evolving role of biomarkers such as KIM-1 in refining risk stratification and highlighted emerging innovations that may reshape how kidney cancer is both imaged and therapeutically targeted.

In this video, Jennifer Miles-Thomas, MD, recaps a SUFU 2026 discussion on leveraging surgeon–APP collaborations in urology.

In a controlled silicone kidney model, CVAC 2.0 outperformed a FANS sheath system for moderate-to-larger stone fragments across clearance efficiency, residual volume, and surgeon ergonomics, though the authors note the model was designed to isolate aspiration mechanics rather than replicate full clinical procedures.

Akanksha Mehta, MD, MS, highlights key recommendations on pre-vasectomy counseling from the American Urological Association’s 2026 Vasectomy Guideline.

Stacy Loeb, MD, MSc, discusses emerging data on microplastics and prostate cancer and highlights practical steps to reduce plastic exposure.

Michelle Van Kuiken, MD, highlights a SWIU 2026 panel discussion on setting boundaries.

Jonathan F. Anker, MD, PhD, discusses findings from the phase 2 HCRN GU 20-444 trial, evaluating a response-adapted, bladder-sparing approach using pembrolizumab monotherapy in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin chemotherapy.

High-powered holmium and thulium laser platforms are expanding ureteroscopic options for complex patients, including those on anticoagulation, while emerging technologies such as Break Wave lithotripsy and ultrasonic propulsion may offer future office-based alternatives to traditional surgical stone management.

Daniel George, MD, discusses key efficacy findings from the phase 3 CAPItello-281 trial evaluating capivasertib plus abiraterone vs placebo plus abiraterone in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.